Benchmark Platform: When NMT controller is under Closed-Loop Control, the main target control results shall be statistically achieved; e.g. time in margin greater than X%, drug infusion less than Xml/hour. This is true for varying control parameters (e.g. Target NMT, type of model , noise level, etc). Potential Partners (BUT, QRTech, and RGB).

Test Case Services Provider: FMEA, and FTA, that are necessary for arguing about HARA (Hazards analysis and Risk Assessment) for certification-aware domains. Preconditions: A new Test Case is injected in the TestBench Platform. Evaluate the new Hazards involved, FTA, FMEA associated, and compliance of device to norms. Expected results: The device performs well as indicated in Test Case 1, and in accordance to norms.

Test Case Services Provider: FMEA, and FTA, that are necessary for arguing about HARA (Hazards analysis and Risk Assessment) for certification-aware domains. Partners INTECS, TRC, UCLM, QRTECH and RGB. Input conditions / steps;

HiL Manager tool sends the dose to the NMT model that simulates the NMT reaction to the dose.

The Controller calculates the new relaxant dose value to inject and sends it to the Infusion pump and to the HiL Manager Tool. Controller generates random sequences of infusion (initial bolus, continuous infusion). Recovery time to half concentration of drug in plasma is in expected range (half-life), error is < 20%; Intubation time is in expected range, error is < 20%

Model based safety analysis (MBSA) and risk mitigation. Define the requirements that a system has to fulfil, along with the procedures that have to be developed, in order to ensure a consistent safety level during the overall system lifecycle;